Key result
Aberrant carotid body activity drives arterial chemoreflex sensitivity in cardiometabolic disease, offering a novel pharmacological target.
Why the study?
Removing or denervating carotid bodies to treat aberrant arterial chemoreflex activity in cardiometabolic diseases causes serious side effects, prompting interest in selective pharmacological targeting of carotid body receptors and pathways.
Pharmacological modulation of specific carotid body receptors offers a promising therapeutic strategy for cardiometabolic diseases, potentially avoiding the severe respiratory side effects associated with surgical denervation.
Answers are grounded in this paper and cite their sources.
May support carotid body receptor modulation in cardiometabolic disease; leaves open confirmation in prospective trials.
This review resulted from a conference on the pathological role of arterial chemoreflex and carotid bodies in cardiometabolic diseases held at the 27th Congress of the Polish Cardiac Society in September 2023 in Poznan, Poland. It reflects the contribution of Polish researchers and their international collaborations, which have been fundamental in the development of the field. Aberrant activity of the carotid bodies leads to both high tonicity and increased sensitivity of the arterial chemoreflex with resultant sympathoexcitation in chronic heart failure, resistant hypertension and obstructive sleep apnoea. This observation has led to several successful attempts of removing or denervating the carotid bodies as a therapeutic option in humans. Regrettably, such interventions are accompanied by serious respiratory and acid-base balance side-effects. Rather than a single stereotyped reaction, arterial chemoreflex comprises an integrative multi-system response to a variety of stimulants and its specific reflex components may be individually conveyed at varying intensities. Recent research has revealed that carotid bodies express diverse receptors, synthesize a cocktail of mediators, and respond to a plethora of metabolic, hormonal and autonomic nervous stimuli. This state-of-the-art summary discusses exciting new discoveries regarding GLP-1 receptors, purinergic receptors, the glutamate-GABA system, efferent innervation and regulation of blood flow in the carotid body and how they open new avenues for novel pharmacological treatments selectively targeting specific receptors, mediators and neural pathways to correct distinct responses of the carotid body-evoked arterial chemoreflex in cardiometabolic diseases. The carotid body offers novel and advantageous therapeutic opportunities for future consideration by trialists.
No takes yet. Share an insight, caveat, or question.
Żera et al. (2025) conducted a review in Cardiometabolic disorders (heart failure, hypertension, sleep apnoea, diabetes). Carotid body targeted interventions was evaluated. Aberrant activity of the carotid body leads to high tonicity and increased sensitivity of the arterial chemoreflex in cardiometabolic disorders, offering a target for novel pharmacological treatments.
Synapse has enriched 10 related papers. Consider them for comparative context: